Reprogramming Donor T cells for Adoptive Immunotherapy

ImmunotherapyVol. 5, No. 12 CommentaryReprogramming donor T cells for adoptive immunotherapyMarkus Y MaparaMarkus Y MaparaDepartment of Medicine, Division of Hematoloy/Oncology & Columbia Center for Translational Immunology (CCTI), Columbia University, College of Physicians & Surgeons, 177Ft. Washington Avenue, MHB – 6GN435, New York, NY 10032, USA. Published Online:27 Nov 2013https://doi.org/10.2217/imt.13.139AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: GVHDmemoryPLZFT cellsReferences1 Barnes DW, Loutit JF. Treatment of murine leukaemia with x-rays and homologous bone marrow. II. Br. J. Haematol.3,241–252 (1957).Crossref, Medline, CAS, Google Scholar2 Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood75,555–562 (1990).Crossref, Medline, CAS, Google Scholar3 Gooley TA, Chien JW, Pergam SA et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N. Engl. J. Med.363,2091–2101 (2010).Crossref, Medline, CAS, Google Scholar4 Chen BJ, Cui X, Sempowski GD, Liu C, Chao NJ. Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. Blood103,1534–1541 (2004).Crossref, Medline, CAS, Google Scholar5 Di Ianni M, Falzetti F, Carotti A et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood117,3921–3928 (2011).Crossref, Medline, CAS, Google Scholar6 Reddy P, Sun Y, Toubai T et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest.118,2562–2573 (2008).Medline, CAS, Google Scholar7 Reddy P, Maeda Y, Hotary K et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl Acad. Sci. USA101,3921–3926 (2004).Crossref, Medline, CAS, Google Scholar8 Leng C, Gries M, Ziegler J et al. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp. Hematol.34,776–787 (2006).Crossref, Medline, CAS, Google Scholar9 Reshef R, Luger SM, Hexner EO et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N. Engl. J. Med.367,135–145 (2012).Crossref, Medline, CAS, Google Scholar10 Kalos M, Levine BL, Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl Med.3,95ra73 (2011).Crossref, Medline, CAS, Google Scholar11 Grupp SA, Kalos M, Barrett D et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med.368,1509–1518 (2013).Crossref, Medline, CAS, Google Scholar12 Linette GP, Stadtmauer EA, Maus MV et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood122,863–871 (2013).Crossref, Medline, CAS, Google Scholar13 Cameron BJ, Gerry AB, Dukes J et al. Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med.5,197ra103 (2013).Crossref, Medline, CAS, Google Scholar14 Vogtenhuber C, Bucher C, Highfill SL et al. Constitutively active Stat5b in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses. Blood116,466–474 (2010).Crossref, Medline, CAS, Google Scholar15 Ma H, Lu C, Ziegler J et al. Absence of Stat1 in donor CD4(+) T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. J. Clin. Invest.121,2554–2569 (2011).Crossref, Medline, CAS, Google Scholar16 Ghosh A, Holland AM, Dogan Y et al. PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD. Cancer Res.73,4687–4696 (2013).Crossref, Medline, CAS, Google Scholar17 Chen Z, Brand NJ, Chen A et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J.12,1161–1167 (1993).Crossref, Medline, CAS, Google Scholar18 Suliman BA, Xu D, Williams BR. The promyelocytic leukemia zinc finger protein: two decades of molecular oncology. Front. Oncol.2,74 (2012).Crossref, Medline, Google Scholar19 Xu D, Holko M, Sadler AJ et al. Promyelocytic leukemia zinc finger protein regulates interferon-mediated innate immunity. Immunity30,802–816 (2009).Crossref, Medline, CAS, Google Scholar20 Kovalovsky D, Uche OU, Eladad S et al. The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat. Immunol.9,1055–1064 (2008).Crossref, Medline, CAS, Google Scholar21 Kovalovsky D, Alonzo ES, Uche OU, Eidson M, Nichols KE, Sant'Angelo DB. PLZF induces the spontaneous acquisition of memory/effector functions in T cells independently of NKT cell-related signals. J. Immunol.184,6746–6755 (2010).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 5, No. 12 Follow us on social media for the latest updates Metrics Downloaded 33 times History Published online 27 November 2013 Published in print December 2013 Information© Future Medicine LtdKeywordsGVHDmemoryPLZFT cellsFinancial & competing interests disclosureThis work was supported by the NIH RO1 HL093716. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download